Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid interactome profiling by massive sequencing.
Di Niro R, Sulic AM, Mignone F, D'Angelo S, Bordoni R, Iacono M, Marzari R, Gaiotto T, Lavric M, Bradbury AR, Biancone L, Zevin-Sonkin D, De Bellis G, Santoro C, Sblattero D. Di Niro R, et al. Among authors: sulic am. Nucleic Acids Res. 2010 May;38(9):e110. doi: 10.1093/nar/gkq052. Epub 2010 Feb 9. Nucleic Acids Res. 2010. PMID: 20144949 Free PMC article.
Transglutaminase 2-specific coeliac disease autoantibodies induce morphological changes and signs of inflammation in the small-bowel mucosa of mice.
Kalliokoski S, Piqueras VO, Frías R, Sulic AM, Määttä JA, Kähkönen N, Viiri K, Huhtala H, Pasternack A, Laurila K, Sblattero D, Korponay-Szabó IR, Mäki M, Caja S, Kaukinen K, Lindfors K. Kalliokoski S, et al. Among authors: sulic am. Amino Acids. 2017 Mar;49(3):529-540. doi: 10.1007/s00726-016-2306-0. Epub 2016 Aug 9. Amino Acids. 2017. PMID: 27503559
RhoB is associated with the anti-angiogenic effects of celiac patient transglutaminase 2-targeted autoantibodies.
Martucciello S, Lavric M, Toth B, Korponay-Szabo I, Nadalutti C, Myrsky E, Rauhavirta T, Esposito C, Sulic AM, Sblattero D, Marzari R, Mäki M, Kaukinen K, Lindfors K, Caja S. Martucciello S, et al. Among authors: sulic am. J Mol Med (Berl). 2012 Jul;90(7):817-26. doi: 10.1007/s00109-011-0853-0. Epub 2012 Jan 6. J Mol Med (Berl). 2012. PMID: 22223195
Celiac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics.
Kalliokoski S, Sulic AM, Korponay-Szabó IR, Szondy Z, Frias R, Perez MA, Martucciello S, Roivainen A, Pelliniemi LJ, Esposito C, Griffin M, Sblattero D, Mäki M, Kaukinen K, Lindfors K, Caja S. Kalliokoski S, et al. Among authors: sulic am. PLoS One. 2013 Jun 18;8(6):e65887. doi: 10.1371/journal.pone.0065887. Print 2013. PLoS One. 2013. PMID: 23824706 Free PMC article.
Transglutaminase as a therapeutic target for celiac disease.
Sulic AM, Kurppa K, Rauhavirta T, Kaukinen K, Lindfors K. Sulic AM, et al. Expert Opin Ther Targets. 2015 Mar;19(3):335-48. doi: 10.1517/14728222.2014.985207. Epub 2014 Nov 20. Expert Opin Ther Targets. 2015. PMID: 25410283 Review.
Current status of drugs in development for celiac disease.
Kurppa K, Hietikko M, Sulic AM, Kaukinen K, Lindfors K. Kurppa K, et al. Among authors: sulic am. Expert Opin Investig Drugs. 2014 Aug;23(8):1079-91. doi: 10.1517/13543784.2014.916274. Epub 2014 May 7. Expert Opin Investig Drugs. 2014. PMID: 24806736 Review.
Wnt target gene Ascl4 is dispensable for skin appendage development.
Papagno V, Sulic AM, Satta JP, Hoshiar AK, Kumar V, Jernvall J, Mikkola ML. Papagno V, et al. Among authors: sulic am. Int J Dev Biol. 2024 May 13. doi: 10.1387/ijdb.240007vp. Online ahead of print. Int J Dev Biol. 2024. PMID: 38770834 Free article.
12 results